Michael R Hayden bought $1.1M of Ionis Pharmaceuticals (IONS)
Executed Jul 30, disclosed Jul 31, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Jul 31), the stock returned +14.5% (delay-adjusted); from the execution session (Jul 30), +15.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
Michael R Hayden (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Ionis Pharmaceuticals, Inc. (IONS). Across 2 priced purchase filings, the average 21-session return was +14.6% from execution and +8.8% from disclosure (delay-adjusted; derived). The largest single filing was $1.1M of IONS (20,000 sh across 2 lots, as filed), executed Jul 30.
Healthcare · Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→15,000 sh × $31.86
Exec May 1 2025
Filed May 2 2025 · 5:30 PM ET